Is the light chain subcellular localization an important factor in botulinum toxin duration of action?

Movement Disorders

Volumn 19, Issue SUPPL. 8, 2004, Pages

  Fernández Salas, Ester ^a   Ho, Helen ^a   Garay, Patton ^a   Steward, Lance E ^a   Aoki, K Roger ^a  

^a ALLERGAN INC   (United States)

Author keywords

Botulinum neurotoxin; Duration; Light chain; SNARE; Subcellular localization

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; NEUROTRANSMITTER; PROTEINASE; ZINC; GLUCOSE; GREEN FLUORESCENT PROTEIN; MEMBRANE PROTEIN; NERVE PROTEIN; NEUROTOXIN; PHOTOPROTEIN; SNAP25 PROTEIN, HUMAN; SNAP25 PROTEIN, RAT; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; CYTOSOL; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME SUBSTRATE; EXOCYTOSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MEMBRANE FUSION; MEMBRANE VESICLE; MOTONEURON; NERVE CELL CULTURE; NERVE CELL INHIBITION; NERVE CELL MEMBRANE; NEUROLOGIC DISEASE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SEROTYPE; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL LINE; CLASSIFICATION; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; DOSE RESPONSE; DRUG EFFECT; EMBRYO; HAMSTER; KIDNEY; METABOLISM; METHODOLOGY; MOLECULAR CLONING; NERVE CELL; PHYSIOLOGY; RAT; SERODIAGNOSIS; TIME;

AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; BOTULINUM TOXINS; CELL DIFFERENTIATION; CELL LINE; CLONING, MOLECULAR; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO; EXOCYTOSIS; GLUCOSE; GREEN FLUORESCENT PROTEINS; HUMANS; KIDNEY; LUMINESCENT PROTEINS; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; NERVE TISSUE PROTEINS; NEURONS; NEUROTOXINS; PRECIPITIN TESTS; RATS; SUBCELLULAR FRACTIONS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TIME FACTORS; TRANSFECTION;

EID: 3242797403     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20006     Document Type: Article

References (32)

1. Dolly JO, Lisk G, Foran PG, et al. Insights into the extended duration of neuroparalysis by Botulinum Neurotoxin A relative to the other shorter-actin serotypes: differences between motor nerve terminals and cultured neurons. In: Brin MF, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams and Wilkins; 2002. p 91-102.
2. Lacy DB, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 1999;291:1091-1104.
3. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000;80:717-766.
4. Chaddock JA, Melling J. Clostridium botulinum and associated neurotoxins. In: Sussman M, editor. Molecular medical microbiology. San Diego: Academic Press; 2001. p 1141-1152.
5. Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 2003;22:454-466.
6. Jurasinski CV, Lieth E, Dang Do AN, Schengrund CL. Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. Toxicon 2001;39: 1309-1315.
7. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, Johnson E, Smith L, Aoki KR, Dolly JO. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 2003;278: 1363-1371.
8. Naumann M. Treatment of focal hyperhidrosis with Botulinum toxin A. In: Brin MF, Hallett M, Jankovic J, editor. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams and Wilkins; 2002. p 303-308.
9. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997; 49:189-194.
10. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998;5:898-902.
11. Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 2000;7:693-699.
12. Williamson LC, Bateman KE, Clifford JC, Neale EA. Neuronal sensitivity to tetanus toxin requires gangliosides. J Biol Chem 1999;274:25173-25180.
13. Herreros J, Lalli G, Schiavo G. C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor. Biochem J 2000;347(Pt 1):199-204.
14. Herreros J, Schiavo G. Lipid microdomains are involved in neurospecific binding and internalisation of clostridial neurotoxins. Int J Med Microbiol 2002;291:447-453.
15. Schmid MF, Robinson JP, DasGupta BR. Direct visualization of botulinum neurotoxin-induced channels in phospholipid vesicles. Nature 1993;364:827-830.
16. Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 2003;10:13-18.
17. Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000;82:427-446.
18. Rizo J, Sudhof TC. Snares and Munc18 in synaptic vesicle fusion. Nat Rev Neurosci 2002;3:641-653.
19. Blasi J, Chapman ER, Yamasaki S, Binz T, Niemann H, Jahn R. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J 1993;12:4821-4828.
20. Foran P, Lawrence GW, Shone CC, Foster KA, Dolly JO. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry 1996;35:2630-2636.
21. Aoki KR. Immunologic and other properties of therapeutic botulinum toxin serotypes. In: Brin MF, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams and Wilkins; 2002. p 103-113.
22. O'Sullivan GA, Mohammed N, Foran PG, Lawrence GW, Oliver Dolly J. Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25. Identification of the minimal essential C-terminal residues. J Biol Chem 1999;274:36897-36904.
23. Keller JE, Neale EA, Oyler G, Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 1999; 456:137-142.
24. Adler M, Keller JE, Sheridan RE, Deshpande SS. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 2001;39:233-243.
25. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 1998;256: 135-138.
26. Chen F, Foran P, Shone CC, Foster KA, Melling J, Dolly JO. Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3-L1 adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present. Biochemistry 1997;36:5719-5728.
27. Johnson EA, Bradshaw M. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon 2001;39: 1703-1722.
28. Martinez-Arca S, Alberts P, Galli T. Clostridial neurotoxin-insensitive vesicular SNAREs in exocytosis and endocytosis. Biol Cell 2000;92:449-453.
29. Huang X, Wheeler MB, Kang YH, Sheu L, Lukacs GL, Trimble WS, Gaisano HY. Truncated SNAP-25 (1-197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells. Mol Endocrinol 1998;12:1060-1070.
30. Lang J, Zhang H, Vaidyanathan VV, Sadoul K, Niemann H, Wollheim CB. Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal beta-cells. FEBS Lett 1997;419:13-17.
31. Boyd RS, Duggan MJ, Shone CC, Foster KA. The effect of botulinum neurotoxins on the release of insulin from the insulinoma cell lines HIT-15 and RINm5F. J Biol Chem 1995;270: 18216-18218.
32. Verheyden J, Blitzer A, Brin MF. Other noncosmetic uses of BOTOX. Semin Cutan Med Surg 2001;20:121-126.